ArticleProstate cancer2026
Long-Term Observed Risk of Clinically Significant Prostate Cancer After Negative mpMRI and Systematic Biopsy in Biopsy-Naïve Men: A MULTIPROS Subanalysis.
Article in Prostate cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: mpMRI is now widely used before prostate biopsy and has improved the detection of clinically significant prostate cancer (csPCa). However, the subsequent risk of csPCa among men with both negative mpMRI and negative systematic biopsy (SBx) remains uncertain. Purpose: To evaluate the observed medium-term risk of csPCa in biopsy-naïve men with initially negative mpMRI and negative SBx. Methods: This post hoc longitudinal follow-up subanalysis included biopsy-naïve men from the prospective multicenter MULTIPROS trial who had negative baseline mpMRI (PI-RADS ≤ 2) and negative SBx. Of the 582 enrolled men, 169 had negative mpMRI; 138 underwent baseline SBx, of whom 8 had csPCa, and 31 had < 12 months of follow-up, leaving 99 men for analysis. Follow-up was PSA-based, with repeat mpMRI and biopsy performed when clinically indicated. Kaplan-Meier analysis estimated csPCa-free survival. Results: During a mean follow-up of 61.8 ± 22.1 months, four patients were diagnosed with csPCa (4/99; 4.0%). The mean time from initial negative mpMRI to csPCa diagnosis was 68.3 ± 22.4 months. Repeat biopsy was performed in 16 patients. csPCa-free survival was 100% at 24 months and 97.3% at 60 months (95% CI: 93.7%-100%). Conclusion: In this selected cohort of biopsy-naïve men with both negative mpMRI and negative SBx, the observed incidence of csPCa during medium-term follow-up was low but based on only four events. Because repeat imaging and biopsy were selectively triggered rather than systematically performed, the true incidence of csPCa may be underestimated. Continued PSA-based monitoring, with repeat mpMRI and biopsy when clinically indicated, remains important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.